PDCD1 and neoplasm: Conventional therapies usually target a particular molecule in the tumor cells, in which most tumor responses last until the cancer develops a way to bypass the blocked pathway, whereas PD-1 blockade releasing negative regulators of immune checkpoints is applicable to a wide range of malignancies as well as provides long-lasting responses.